Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
113%(9 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
6
67%
Ph phase_3
3
33%

Phase Distribution

0

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (66.7%)
Phase 33 (33.3%)

Trials by Status

terminated111%
completed889%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

NCT02741128
completedphase_2

Efficacy and Safety of Dengue Vaccine in Healthy Children

NCT00842530
completedphase_3

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

NCT02993757
completedphase_3

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

NCT02979535
terminatedphase_3

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

NCT02992418
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02741128Phase 2

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Completed
NCT00842530Phase 2

Efficacy and Safety of Dengue Vaccine in Healthy Children

Completed
NCT02993757Phase 3

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Completed
NCT02979535Phase 3

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Completed
NCT02992418Phase 3

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Terminated
NCT01943825Phase 2

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Completed
NCT02628444Phase 2

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Completed
NCT00993447Phase 2

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Completed
NCT00880893Phase 2

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9